Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents

Debomoy Lahiri, J. T. Rogers, N. H. Greig, K. Sambamurti

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is characterized by progressive dementia caused by the loss of the presynaptic markers of the cholinergic system in the brain areas related to memory and learning and brain deposits of amyloid beta peptide (Aβ) and neurofibrillary tangles (NFT). A small fraction of early onset familial AD (FAD) is caused by mutations in genes, such as the β-amyloid precursor protein (APP) and presenilins that increase the load of Aβ in the brain. These studies together with findings that Aβ is neurotoxic in vitro, provide evidence that some aggregates of this peptide are the key to the pathogenesis of AD. The yield of Aβ and the processing and turnover of APP are regulated by a number of pathways including apolipoprotein E, cholesterol and cholinergic agonists. Early studies showed that muscarinic agonists increased APP processing within the Aβ sequence (sAPPα). More recently, we have presented evidence showing that some, but not all, anticholinesterases reduce secretion of sAPPα as well as Aβ into the media suggesting that cholinergic agonists; modulate Aβ levels by multiple mechanisms. Herein we review the recent advances in understanding the function of cholinesterase (ChE) in the brain and the use of ChE-inhibitors in AD. We propose and support the position that the influence of cholinergic stimulation on amyloid formation is critical in light of the early targeting of the cholinergic basal forebrain in AD and the possibility that maintenance of this cholinergic tone might slow amyloid deposition. In this context, the dual action of certain cholinesterase inhibitors on their ability to increase acetylcholine levels and decrease amyloid burden assumes significance as it may identify a single drug to both arrest the progression of the disease as well as treat its symptoms. A new generation of acetyl- and butyryl cholinesterase inhibitors is being studied and tested in human clinical trials for AD. We critically discuss recent trends in AD research, from molecular and genetic to clinical areas, as it relates to the effects of cholinergic agents and their secondary effects on Aβ. Finally, we examine different neurobiological mechanisms that provide the basis of new targets for AD drug development.

Original languageEnglish
Pages (from-to)3111-3119
Number of pages9
JournalCurrent Pharmaceutical Design
Volume10
Issue number25
DOIs
StatePublished - 2004

Fingerprint

Cholinesterase Inhibitors
Alzheimer Disease
Cholinergic Agents
Amyloid beta-Protein Precursor
Amyloid
Cholinergic Agonists
Brain
Presenilins
Muscarinic Agonists
Neurofibrillary Tangles
Aptitude
Amyloid beta-Peptides
Cholinesterases
Apolipoproteins E
Pharmaceutical Preparations
Acetylcholine
Dementia
Disease Progression
Molecular Biology
Cholesterol

Keywords

  • Acetylcholine
  • Alzheimer's disease
  • Anticholinesterase
  • ApoE
  • APP gene
  • BACE
  • Beta-amyloid
  • Butyrylcholine
  • Cholinergic agents
  • Cholinesterase
  • Cholinomimetic drugs
  • Dementia
  • Oxidative stress
  • Phenserine
  • Secretase
  • Tau protein

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. / Lahiri, Debomoy; Rogers, J. T.; Greig, N. H.; Sambamurti, K.

In: Current Pharmaceutical Design, Vol. 10, No. 25, 2004, p. 3111-3119.

Research output: Contribution to journalArticle

Lahiri, Debomoy ; Rogers, J. T. ; Greig, N. H. ; Sambamurti, K. / Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. In: Current Pharmaceutical Design. 2004 ; Vol. 10, No. 25. pp. 3111-3119.
@article{1d54d7a7587b45deae2ac337c9f8aa6f,
title = "Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents",
abstract = "Alzheimer's disease (AD) is characterized by progressive dementia caused by the loss of the presynaptic markers of the cholinergic system in the brain areas related to memory and learning and brain deposits of amyloid beta peptide (Aβ) and neurofibrillary tangles (NFT). A small fraction of early onset familial AD (FAD) is caused by mutations in genes, such as the β-amyloid precursor protein (APP) and presenilins that increase the load of Aβ in the brain. These studies together with findings that Aβ is neurotoxic in vitro, provide evidence that some aggregates of this peptide are the key to the pathogenesis of AD. The yield of Aβ and the processing and turnover of APP are regulated by a number of pathways including apolipoprotein E, cholesterol and cholinergic agonists. Early studies showed that muscarinic agonists increased APP processing within the Aβ sequence (sAPPα). More recently, we have presented evidence showing that some, but not all, anticholinesterases reduce secretion of sAPPα as well as Aβ into the media suggesting that cholinergic agonists; modulate Aβ levels by multiple mechanisms. Herein we review the recent advances in understanding the function of cholinesterase (ChE) in the brain and the use of ChE-inhibitors in AD. We propose and support the position that the influence of cholinergic stimulation on amyloid formation is critical in light of the early targeting of the cholinergic basal forebrain in AD and the possibility that maintenance of this cholinergic tone might slow amyloid deposition. In this context, the dual action of certain cholinesterase inhibitors on their ability to increase acetylcholine levels and decrease amyloid burden assumes significance as it may identify a single drug to both arrest the progression of the disease as well as treat its symptoms. A new generation of acetyl- and butyryl cholinesterase inhibitors is being studied and tested in human clinical trials for AD. We critically discuss recent trends in AD research, from molecular and genetic to clinical areas, as it relates to the effects of cholinergic agents and their secondary effects on Aβ. Finally, we examine different neurobiological mechanisms that provide the basis of new targets for AD drug development.",
keywords = "Acetylcholine, Alzheimer's disease, Anticholinesterase, ApoE, APP gene, BACE, Beta-amyloid, Butyrylcholine, Cholinergic agents, Cholinesterase, Cholinomimetic drugs, Dementia, Oxidative stress, Phenserine, Secretase, Tau protein",
author = "Debomoy Lahiri and Rogers, {J. T.} and Greig, {N. H.} and K. Sambamurti",
year = "2004",
doi = "10.2174/1381612043383331",
language = "English",
volume = "10",
pages = "3111--3119",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "25",

}

TY - JOUR

T1 - Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents

AU - Lahiri, Debomoy

AU - Rogers, J. T.

AU - Greig, N. H.

AU - Sambamurti, K.

PY - 2004

Y1 - 2004

N2 - Alzheimer's disease (AD) is characterized by progressive dementia caused by the loss of the presynaptic markers of the cholinergic system in the brain areas related to memory and learning and brain deposits of amyloid beta peptide (Aβ) and neurofibrillary tangles (NFT). A small fraction of early onset familial AD (FAD) is caused by mutations in genes, such as the β-amyloid precursor protein (APP) and presenilins that increase the load of Aβ in the brain. These studies together with findings that Aβ is neurotoxic in vitro, provide evidence that some aggregates of this peptide are the key to the pathogenesis of AD. The yield of Aβ and the processing and turnover of APP are regulated by a number of pathways including apolipoprotein E, cholesterol and cholinergic agonists. Early studies showed that muscarinic agonists increased APP processing within the Aβ sequence (sAPPα). More recently, we have presented evidence showing that some, but not all, anticholinesterases reduce secretion of sAPPα as well as Aβ into the media suggesting that cholinergic agonists; modulate Aβ levels by multiple mechanisms. Herein we review the recent advances in understanding the function of cholinesterase (ChE) in the brain and the use of ChE-inhibitors in AD. We propose and support the position that the influence of cholinergic stimulation on amyloid formation is critical in light of the early targeting of the cholinergic basal forebrain in AD and the possibility that maintenance of this cholinergic tone might slow amyloid deposition. In this context, the dual action of certain cholinesterase inhibitors on their ability to increase acetylcholine levels and decrease amyloid burden assumes significance as it may identify a single drug to both arrest the progression of the disease as well as treat its symptoms. A new generation of acetyl- and butyryl cholinesterase inhibitors is being studied and tested in human clinical trials for AD. We critically discuss recent trends in AD research, from molecular and genetic to clinical areas, as it relates to the effects of cholinergic agents and their secondary effects on Aβ. Finally, we examine different neurobiological mechanisms that provide the basis of new targets for AD drug development.

AB - Alzheimer's disease (AD) is characterized by progressive dementia caused by the loss of the presynaptic markers of the cholinergic system in the brain areas related to memory and learning and brain deposits of amyloid beta peptide (Aβ) and neurofibrillary tangles (NFT). A small fraction of early onset familial AD (FAD) is caused by mutations in genes, such as the β-amyloid precursor protein (APP) and presenilins that increase the load of Aβ in the brain. These studies together with findings that Aβ is neurotoxic in vitro, provide evidence that some aggregates of this peptide are the key to the pathogenesis of AD. The yield of Aβ and the processing and turnover of APP are regulated by a number of pathways including apolipoprotein E, cholesterol and cholinergic agonists. Early studies showed that muscarinic agonists increased APP processing within the Aβ sequence (sAPPα). More recently, we have presented evidence showing that some, but not all, anticholinesterases reduce secretion of sAPPα as well as Aβ into the media suggesting that cholinergic agonists; modulate Aβ levels by multiple mechanisms. Herein we review the recent advances in understanding the function of cholinesterase (ChE) in the brain and the use of ChE-inhibitors in AD. We propose and support the position that the influence of cholinergic stimulation on amyloid formation is critical in light of the early targeting of the cholinergic basal forebrain in AD and the possibility that maintenance of this cholinergic tone might slow amyloid deposition. In this context, the dual action of certain cholinesterase inhibitors on their ability to increase acetylcholine levels and decrease amyloid burden assumes significance as it may identify a single drug to both arrest the progression of the disease as well as treat its symptoms. A new generation of acetyl- and butyryl cholinesterase inhibitors is being studied and tested in human clinical trials for AD. We critically discuss recent trends in AD research, from molecular and genetic to clinical areas, as it relates to the effects of cholinergic agents and their secondary effects on Aβ. Finally, we examine different neurobiological mechanisms that provide the basis of new targets for AD drug development.

KW - Acetylcholine

KW - Alzheimer's disease

KW - Anticholinesterase

KW - ApoE

KW - APP gene

KW - BACE

KW - Beta-amyloid

KW - Butyrylcholine

KW - Cholinergic agents

KW - Cholinesterase

KW - Cholinomimetic drugs

KW - Dementia

KW - Oxidative stress

KW - Phenserine

KW - Secretase

KW - Tau protein

UR - http://www.scopus.com/inward/record.url?scp=4544295150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544295150&partnerID=8YFLogxK

U2 - 10.2174/1381612043383331

DO - 10.2174/1381612043383331

M3 - Article

C2 - 15544501

AN - SCOPUS:4544295150

VL - 10

SP - 3111

EP - 3119

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 25

ER -